|Mr. Charles R. Kummeth||CEO, Pres & Director||2.56M||N/A||1960|
|Mr. James T. Hippel||Sr. VP of Fin. & CFO||968.88k||N/A||1971|
|Ms. Brenda S. Furlow||Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer||643.23k||N/A||1958|
|Mr. N. David Eansor||Pres of Protein Sciences Segment||866.28k||N/A||1961|
|Mr. Gerry Andros||VP of Sales and Marketing||N/A||N/A||N/A|
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers reagent solutions, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera reagents, and cell selection technologies. This segment also provides analytical solutions, including manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. In addition, it offers various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Corporation’s ISS Governance QualityScore as of July 29, 2019 is 1. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 1; Compensation: 3.